

Inserm Workshop 280


Exploiting the full potential of Nanobodies®: from research tools to therapeutics



REGISTRATION DEADLINE: June 21, 2024

ORGANIZERS: Nicolas BERY (CRCT, UMR1037, Toulouse), Patrick CHAMES (CRCM, Inserm 1068, CNRS 7258, Marseille) and Brigitte KERFELEC (CRCM, Inserm 1068, CNRS 7258, Marseille)

AIMS: The objective of this workshop is to provide participants with a global and updated vision on the applications of nanobodies in biology, whether for fundamental and mechanistic studies or for translational approaches in the medical field through four axes.



PHASE I – CRITICAL ASSESSMENT

September 25-27, 2024 in Bordeaux

KEYNOTE LECTURE

Serge MUYLDERMANS (Vrije Universiteit Brussel, BEL)

NANOBODIES IN STRUCTURAL BIOLOGY

Jan STEYEART (Vrije Universiteit Brussel, BEL), Kaspar LOCHER (ETH, Zurich, CHE), Philippe LEONE (LISM, Marseille, FRA) and Guillaume DUMENIL (Institut Pasteur, Paris, FRA)

NANOBODIES IN CELL BIOLOGY AND IMAGING

Ulrich ROTHBAUER (University of Tübingen, DEU), Laura DASSAMA (University of Stanford, USA), Felipe OPAZO (University of Göttingen, DEU) and John DINGUS (University of Harvard, Boston, USA)

NANOBODIES AS DIAGNOSTIC TOOLS

Sophie HERNOT (Vrije Universiteit Brussel, BEL), Ploegh HIDDE (Boston Children's Hospital, Boston, USA), Pierre LAFAYE (Institut Pasteur, Paris, FRA) and René HÄGERLING (Institute of Medical and Human Genetics, Charité - Universitätsmedizin Berlin, Germany BIH Center for Regenerative Therapies, Berlin Institute of Health, DEU)

NANOBODIES AS THERAPEUTICS

Friedrich KOCH-NOLTE (University Medical Center Hamburg, DEU), Martine SMIT (Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, NLD), Philippe RONDARD (Institute of functional genomics, Montpellier, FRA) and Pauline VAN HELDEN (LAVA Therapeutics, Utrecht, NLD)



PHASE II – TECHNICAL WORKSHOP

Date released later – CRCT, Toulouse

Date released later – CRCM, Marseille

One practical training session will be held on the use of nanobodies in cell biology to show that targeted degradation of a tagged protein can be useful to determine the degradability of a target but also to study its function in cells/organism. Another practical training session will focus on the use of nanobody-based immune cell engagers to trigger immune cell cytotoxicity using real time and end-point cell viability assays.

SELECTION: Six trainees will be selected for each city among Phase I participants

Information and registration:
<https://ateliersinserm.dakini-pco.com>